Agrawal Khushboo Ph.D.

Agrawal Khushboo Ph.D.'s picture
Phone: +420 585632174, +420 608706055
Curriculum Vitae: download
LinkedIn

I pursue the goal of learning and contributing my expertise to the field of cancer drug discovery, and look forward to coordinate and conduct research on the causes of human cancer, to unveil the various prospects of application in my field of interest. My research interest exquisitely lies in cancer epigenetics, mainly involving the study of chemotherapeutic resistance and investigation of novel biomarkers, hence furthering clinical development.


Doctoral training
5-Azacytidine Nucleosides and their Derivatives: Molecular Hallmarks of Drug Resistance & Alternative Therapeutic Regimen
The thesis is mainly focused towards the investigation of the mechanisms of chemotherapeutic resistance to DNA methylation inhibitors. The study will aid to the understanding of the molecular basis of acquired tumor resistance and help in predicting its clinical response, as well as in designing alternative treatment regimens for overcoming resistance.

Status:

Graduated 2010 - 2017

Publications (Impact Factor Journals):

  • [4]
    AGRAWAL, K., V. DAS, P. VYAS a M. HAJDÚCH. Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic. Pharmacology & Therapeutics. 2018, -, -. ISSN 0163-7258. IF: 11.127. PMID: 29454856
  • [3]
    ANNADURAI, N., K. AGRAWAL, P. DŽUBÁK, M. HAJDÚCH a V. DAS. Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease. Cellular and Molecular Life Sciences. 2017, 74(22), 4159-4169. ISSN 1420-682X. IF: 5.788. PMID: 28634681
  • [2]
    AGRAWAL, K., V. DAS, M. OTMAR, M. KRECMEROVA, P. DŽUBÁK a M. HAJDÚCH. Cell-based DNA demethylation detection system for screening of epigenetic drugs in 2D, 3D, and xenograft models. Cytometry A. 2016, -, -. ISSN 1552-4922 . IF: 3.222. PMID: 27911980
  • [1]
    HRUBY, M., K. AGRAWAL, O. POLICIANOVA, J. BRUS, J. SKOPAL, P. SVEC, M. OTMAR, P. DŽUBÁK, P. STEPANEK a M. HAJDÚCH. Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic. 2016, 160(2), 222-230. ISSN 1213-8118 . IF: 0.894. PMID: 27003313

Patents, Utility models & other IP's :

[1] METHOD OF PREDICTING THE TUMOR RESPONSE TO DNA METHYLATION INHIBITORS AND ALTERNATIVE THERAPEUTIC REGIMENS FOR OVERCOMING RESISTANCE, EP 14161897.5
  1. Patent appl. EP 14161897.5 (ASH1L), Patent: EP 2924125, Granted: 17. 6. 2017, Ownership: Palacky University Olomouc, Inventors: Agrawal Khushboo, Frydrych Ivo, Džubák PetrHajdúch Marián
  2. Patent appl. EP 15717786.6 (BRD4), Patent: EP 3122902, Granted: 16. 5. 2018, Ownership: Palacký University, Olomouc, Inventors: Agrawal KhushbooFrydrych IvoDžubák PetrHajdúch Marián

​Status: Available